Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| CDP-Choline (Citicoline) | NSI-189 | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 250-500 mg/day | 40 mg once daily (for educational context — investigational compound, not approved for any indication) |
| Timing | Morning or split morning/afternoon. With or without food. | Once daily, time of day not definitively established from clinical data. With or without food. |
| Cycle Duration | Ongoing; no cycling required | Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable. |
| Evidence Level | strong_human | moderate_human |
Prodrug that is hydrolyzed to choline and cytidine upon oral ingestion. Choline supports acetylcholine synthesis and phosphatidylcholine membrane repair. Cytidine is converted to uridine, which enhances synaptic membrane synthesis via the Kennedy pathway and upregulates dopamine receptor density. This dual mechanism — cholinergic support plus dopaminergic modulation — is unique among choline sources.
250-500 mg/day
Morning or split morning/afternoon. With or without food.
Ongoing; no cycling required
Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.
40 mg once daily (for educational context — investigational compound, not approved for any indication)
Once daily, time of day not definitively established from clinical data. With or without food.
Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →